Blurbs

Analysts Offer Insights on Healthcare Companies: Tricida (TCDA) and Replimune Group (REPL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tricida (TCDAResearch Report) and Replimune Group (REPLResearch Report).

Tricida (TCDA)

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Hold rating on Tricida, with a price target of $8.00. The company’s shares closed last Thursday at $9.95.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 6.6% and a 47.0% success rate. Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Tricida is a Moderate Buy with an average price target of $18.00.

See Insiders’ Hot Stocks on TipRanks >>

Replimune Group (REPL)

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Replimune Group, with a price target of $36.00. The company’s shares closed last Thursday at $14.38, close to its 52-week low of $13.05.

According to TipRanks.com, Rama is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.1% and a 38.9% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Springworks Therapeutics.

Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $45.40, implying a 225.0% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $44.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TCDA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos